Results 61 to 70 of about 6,343 (174)

Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background With guidelines recommending earlier advanced therapy (AT) use after 5‐ASA failure for patients with moderately‐to‐severely active ulcerative colitis (UC), it is important to explore treatment preferences at the point of escalation to first‐line AT.
Stefan Schreiber, Alissa Walsh, Peter Hur, Laura Panattoni, Brett Hauber, Natalie Land, Josh Coulter, Grace Gahlon, Karolina Wosik, Joseph C. Cappelleri, Melissa Culhane Maravic, Xiang Guo, Anthony Buisson   +12 more
wiley   +1 more source

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

Drug Design, Development and Therapy, 2011
Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first ...
Lilliana Oliveira, Russell D Cohen
doaj  

A novel pH–enzyme-dependent mesalamine colon-specific delivery system

Drug Design, Development and Therapy, 2016
Lei Jin, Yi-cun Ding, Yu Zhang, Xiao-qing Xu, Qin Cao Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China Abstract: The aim of the present study was to ...
Jin L, Ding Y, Zhang Y, Xu X, Cao Q
doaj  

Mesalamine-induced myocarditis following diagnosis of Crohn's disease: A case report

Revista Portuguesa de Cardiologia, 2013
Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. We present the case of a 19-year-old male who developed chest pain two weeks after beginning mesalamine ...
Carlos Galvão Braga, Juliana Martins, Carina Arantes, Vítor Ramos, Catarina Vieira, Alberto Salgado, Sónia Magalhães, Adelino Correia   +7 more
doaj   +1 more source

Mesalamine-induced myopericarditis - A case report

Revista Española de Enfermedades Digestivas, 2016
Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease. We present a 20-year-old woman with ulcerative colitis admitted with chest pain. After thorough investigation she was diagnosed with myopericarditis potentially related to mesalamine.
Bernardo,Sónia, Fernandes,Samuel Raimundo, Araújo-Correia,Luís   +2 more
openaire   +3 more sources

Not Your Typical Ulcerative Colitis Patient [PDF]

Modern Medicine
Background: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD.
Teodora SPATARU, Ana STEMATE, Roxana SADAGURSCHI, Lucian NEGREANU   +3 more
doaj   +1 more source

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

Clinical and Experimental Gastroenterology, 2009
Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj  

Therapeutic potential of mesalamine-probiotic combination in enteric-coated tablet for modulating gut inflammation in IBD

Journal of Applied Pharmaceutical Research
Background: Mesalamine is widely used for inflammatory bowel disease (IBD) due to its local anti-inflammatory action, while probiotics help restore intestinal microbiota and modulate immune responses. Combining both may offer synergistic benefits for IBD
Pratiksha A. Thete, Milind P. Wagh, Vandana S. Nade   +2 more
doaj   +1 more source

Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials

Drug Design, Development and Therapy, 2014
David Pierce,1 Mary Corcoran,2 Patrick Martin,2 Karen Barrett,1 Susi Inglis,1 Peter Preston,2 Thomas N Thompson,3 Sandra K Willsie3 1Shire, Basingstoke, UK; 2Shire, Wayne, PA, USA; 3PRA International, Lenexa, KS, USA Background: MMX® mesalamine is a
Pierce D, Corcoran M, Martin P, Barrett K, Inglis S, Preston P, Thompson TN, Willsie SK   +7 more
doaj  

A rare case of mesalamine-induced eosinophilic pleural effusion

The Journal of Association of Chest Physicians
We present a very rare case of a 47-year-old man with a history of ulcerative colitis (UC), referred to as a case of an undiagnosed bilateral pleural effusion.
Ankit Bhatia, Sharad Joshi, Nitesh Tayal, Maj Gen Darshan Singh Bhakuni, Subhasish Majumdar   +4 more
doaj   +1 more source